A randomized 24-week trial found that rosuvastatin 10 mg plus ezetimibe 10 mg lowered LDL cholesterol more than rosuvastatin 20 mg alone. The study also reported smaller relative liver enzyme increases, with no clinically significant hepatotoxicity in either arm. The result adds incremental comparative evidence for combination lipid-lowering strategies in the context of tolerability, an issue central to long-term adherence. While the brief does not specify the absolute LDL reductions, the direction of effect and liver enzyme safety comparisons are central to the headline outcome. For clinical development and guideline-adjacent stakeholders, the key take-away is a clearer risk-benefit profile when combining ezetimibe with a lower-dose statin.